3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Melanoma
93
Carcinoma, Non-Small-Cell Lung
46
Neoplasms
33
Carcinoma, Renal Cell
24
Neoplasm Metastasis
16
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
12
Small Cell Lung Carcinoma
9
Prostatic Neoplasms
9
Lung Neoplasms
9
Diabetes Mellitus, Insulin-Dependent, 12
9
Advanced Cancer
9
Squamous Cell Carcinoma of Head and Neck
8
Uveal Melanoma
7
Stomach Neoplasms
7
Skin Neoplasms
7
Mesothelioma
7
Kidney Neoplasms
7
Carcinoma, Transitional Cell
7
Recurrence
6
Pancreatic Neoplasms
6
Liver Neoplasms
6
Triple Negative Breast Neoplasms
5
Sarcoma
5
Ovarian Neoplasms
5
Head and Neck Neoplasms
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Solid Tumor
4
Interventions
fluciclovine F-18
2
Positron-Emission Tomography
2
Injections
2
Dexamethasone
2
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
2
tislelizumab
1
technetium 99m 1-(1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)-2-((1-(2-(bis(carboxymethyl)amino)-2-oxoethyl)-1H-imidazol-2-yl)methyl)-9,14-dioxo-2,8,13,15-tetraazaoctadecane-7,12,16,18-tetracarboxylic acid)
1
ricolinostat
1
pomalidomide
1
pembrolizumab
1
lortalamine
1
gossypol acetic acid
1
daratumumab
1
aflibercept
1
Prednisone
1
Oncolytic Virotherapy
1
Octreotide
1
Mitomycin
1
Mammography
1
Lenalidomide
1
Ipilimumab
1
Drug Delivery Systems
1
Docetaxel
1
Diagnosis, Computer-Assisted
1
Daunorubicin
1
Cytarabine
1
Control Groups
1
CPX-351
1
Bevacizumab
1
Antibodies, Monoclonal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Disease
×
Ipilimumab
×
Clear all
NCT04855929
2024-11-08
ANV419-001
Anaveon AG
Phase 1
Completed
55 enrolled